Literature DB >> 16442270

ECNP consensus meeting March 2003 guidelines for the investigation of efficacy in substance use disorders.

W Van den Brink1, S A Montgomery, J M Van Ree, B J van Zwieten-Boot.   

Abstract

Mesh：

Year:  2006        PMID： 16442270     DOI： 10.1016/j.euroneuro.2005.12.003

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN： 0924-977X            Impact factor:   4.600


× No keyword cloud information.
  7 in total

Review 1.  The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda.

Authors:  Mallory J E Loflin; Brian D Kiluk; Marilyn A Huestis; Will M Aklin; Alan J Budney; Kathleen M Carroll; Deepak Cyril D'Souza; Robert H Dworkin; Kevin M Gray; Deborah S Hasin; Dustin C Lee; Bernard Le Foll; Frances R Levin; Joshua A Lile; Barbara J Mason; Aimee L McRae-Clark; Ivan Montoya; Erica N Peters; Tatiana Ramey; Dennis C Turk; Ryan Vandrey; Roger D Weiss; Eric C Strain
Journal:  Drug Alcohol Depend       Date:  2020-04-26       Impact factor: 4.492

2.  Beyond drug use: a systematic consideration of other outcomes in evaluations of treatments for substance use disorders.

Authors:  Stephen T Tiffany; Lawrence Friedman; Shelly F Greenfield; Deborah S Hasin; Ron Jackson
Journal:  Addiction       Date:  2011-10-07       Impact factor: 6.526

3.  Statistical considerations in the choice of endpoint for drug use disorder trials.

Authors:  Garrett M Fitzmaurice; Stuart R Lipsitz; Roger D Weiss
Journal:  Drug Alcohol Depend       Date:  2017-10-18       Impact factor: 4.492

4.  Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials.

Authors:  Dennis M Donovan; George E Bigelow; Gregory S Brigham; Kathleen M Carroll; Allan J Cohen; John G Gardin; John A Hamilton; Marilyn A Huestis; John R Hughes; Robert Lindblad; G Alan Marlatt; Kenzie L Preston; Jeffrey A Selzer; Eugene C Somoza; Paul G Wakim; Elizabeth A Wells
Journal:  Addiction       Date:  2011-07-22       Impact factor: 6.526

Review 5.  The clinical significance of drug craving.

Authors:  Stephen T Tiffany; Jennifer M Wray
Journal:  Ann N Y Acad Sci       Date:  2011-12-16       Impact factor: 5.691

6.  Within-treatment frequency of use versus abstinence as a predictor of longitudinal post-treatment follow-up assessments of drug use.

Authors:  Garrett M Fitzmaurice; Stuart R Lipsitz; Roger D Weiss
Journal:  Drug Alcohol Depend       Date:  2020-01-17       Impact factor: 4.492

7.  Validating the clinical relevance of alternative stimulant use treatment outcome measures by examining their association with 3-month follow-up outcomes.

Authors:  André Q C Miguel; Crystal L Smith; Ekaterina Burduli; John M Roll; Sterling M McPherson
Journal:  Exp Clin Psychopharmacol       Date:  2021-06       Impact factor: 3.492
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.